Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said it started the process required to establish an expanded access program to make its investigational potassium channel inhibitor, Firdapse (amifampridine phosphate or 3,4-DAP phosphate), available to patients in the U.S. diagnosed with Lambert-Eaton myasthenic syndrome through their neuromuscular disease specialists.